TOP News

US: African effort to replicate mRNA vaccine targets disparities

Over 25% of Americans are no longer living in high-transmission counties: Live COVID-19 updates

  Over 25% of Americans are no longer living in high-transmission counties: Live COVID-19 updates More than one-quarter of Americans are now living in a county that no longer has high levels of community transmission of coronavirus. COVID updates.That's a major change from earlier in the pandemic wave driven by the delta variant, when every state was considered to have high levels of community transmission, which the CDC says is 100 cases per 100,000 people per week.

Messenger RNA ( mRNA ) mediates the transfer of genetic information from the cell nucleus to ribosomes in the cytoplasm, where it serves as a template for protein synthesis. RNAi can also be used to shut down translation of viral proteins when a cell is infected by a virus. The RNAi system also has the potential to be exploited therapeutically1 and can prevent the viral RNA from replicating . Below are the TOP FIVE recommended substances to mitigate damage from mRNA vaccines (in no particular order).

mRNA vaccines -- also called "genetic vaccines " -- arise from an innovative biotechnology approach that turns the body's cells into molecular factories to produce proteins that activate a pathogen-specific immune response. The technology holds great promise but also presents significa. This could theoretically occur when the mRNA snippets are pushed into cells via virus replicon particles (VRP), for example, or using other viral delivery methods that rely on viral replication machinery. On the other hand, self- replicating mRNA vaccines allow for injection doses to be incredibly small, since the

CAPE TOWN, South Africa (AP) — In a pair of Cape Town warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world's poorest people.

Scientists re-enact the calibration procedure of equipment at an Afrigen Biologics and Vaccines facility in Cape Town, South Africa, Tuesday Oct. 19, 2021. In a pair of warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world's poor. (AP Photo/Jerome Delay) © Provided by Associated Press Scientists re-enact the calibration procedure of equipment at an Afrigen Biologics and Vaccines facility in Cape Town, South Africa, Tuesday Oct. 19, 2021. In a pair of warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world's poor. (AP Photo/Jerome Delay) Afrigen Managing Director Petro Terblanche poses for a photograph in her office in Cape Town, South Africa, Tuesday, Oct. 19, 2021. A team of young Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. Terblanche said the Cape Town company is aiming to have a version of the Moderna vaccine ready for testing in people within a year and scaled up for commercial production not long after. (AP Photo/Jerome Delay) © Provided by Associated Press Afrigen Managing Director Petro Terblanche poses for a photograph in her office in Cape Town, South Africa, Tuesday, Oct. 19, 2021. A team of young Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. Terblanche said the Cape Town company is aiming to have a version of the Moderna vaccine ready for testing in people within a year and scaled up for commercial production not long after. (AP Photo/Jerome Delay)

The energy in the gleaming labs matches the urgency of their mission to narrow vaccine disparities. By working to replicate Moderna's COVID-19 shot, the scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in both sales and manufacturing.

Fact check: Pfizer's FDA-approved vaccine is available in US

  Fact check: Pfizer's FDA-approved vaccine is available in US The authorization from the FDA changed, but the vaccine didn't. Comirnaty is simply the brand name for Pfizer's shot.On social media, however, some say an FDA-approved COVID-19 vaccine is still not available for American adults.

mRNA -based vaccines promise to meet this need. mRNA -based vaccines exhibit a number of poten-. tial advantages relative to conventional vaccines , namely they (1) involve neither infectious elements. nor a risk of stable integration into the host cell genome; (2) generate humoral and cell-mediated. Self- replication increases the magnitude and du-. ration of construct expression and, consequently, production of the encoded immunogen. In non-human primates (NHP), low doses of self- replicating mRNA vaccine induced en-. hanced immunogen production for an extended duration, where

I would expect an mRNA vaccine to be much less dangerous than traditional delivery methods, but I don’t know if that’s just because it hasn’t been tested enough to even determine what the dangers might be. Does anyone have any ideas or additional reading material? mRNA vaccines utilize translation in host cells to produce a viral protein target . The host immune system then responds to the presence of these viral proteins by producing antibodies, cellular immune responses, and (hopefully) memory B cells.

And they are doing it with unusual backing from the World Health Organization, which is coordinating a vaccine research, training and production hub in South Africa along with a related supply chain for critical raw materials. It's a last resort effort to make doses for people going without, and the intellectual property implications are still murky.

“We are doing this for Africa at this moment, and that drives us,” said Emile Hendricks, a 22-year-old biotechnologist for Afrigen Biologics and Vaccines, the company trying to reproduce the Moderna jab. "We can no longer rely on these big superpowers to come in and save us.”

A sign hangs at an Afrigen Biologics and Vaccines facility in Cape Town, South Africa, Tuesday, Oct. 19, 2021. A team of Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. The scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in both vaccine sales and manufacturing. ​(AP Photo/Jerome Delay) © Provided by Associated Press A sign hangs at an Afrigen Biologics and Vaccines facility in Cape Town, South Africa, Tuesday, Oct. 19, 2021. A team of Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. The scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in both vaccine sales and manufacturing. ​(AP Photo/Jerome Delay)

Some experts see reverse engineering — recreating vaccines from fragments of publicly available information — as one of the few remaining ways to redress the power imbalances of the pandemic. Only 0.7% of vaccines have gone to low-income countries so far, while nearly half have gone to wealthy countries, according to an analysis by the People's Vaccine Alliance.

Trade candidate: Cardinals' Paul DeJong

  Trade candidate: Cardinals' Paul DeJong While DeJong hasn’t been an especially productive hitter in recent seasons, he hasn’t been without value. Defensive metrics have still pegged him as a solid or better defender. Over the past two seasons, DeJong has rated as six runs above average at shortstop by DRS, while Statcast has him at two plays above average. Even average play at shortstop is valuable, and DeJong is probably at least a tick above par defensively.Because of that defensive acumen, DeJong has been valued at around two wins above replacement since the start of 2020 by both FanGraphs and Baseball Reference.

Replicating vaccines offer several rounds of antigen production to. increase the efficacy of immune defence induction [3,8]. This. RNA vaccine development has found a clear level of success, with. most vaccines based on the mRNA trial effort within its project tasks [57]. In this context, reference can be. taken from the reports on Targeting human dendritic cell subsets for improved vaccines .

Since the vaccine targets remain undefined before an outbreak occurs, time remains one of the major hurdles for effective vaccine development. Currently, the average development time for conventional vaccines from preclinical phase is more than 10 years ( 14 ), highlighting the dire need for new The past decades have witnessed the development of a wide array of new vaccination technologies ranging from targeted attenuation techniques of live pathogens to the delivery of biologically engineered protein and peptide antigens as well as viral vector and nucleic acid based antigens.

That WHO, which relies upon the goodwill of wealthy countries and the pharmaceutical industry for its continued existence, is leading the attempt to reproduce a proprietary vaccine demonstrates the depths of the supply disparities.

Caryn Fenner, Afrigen Biologics and Vaccines technical director, is reflected in a mirror inside a research lab in Cape Town, South Africa, Tuesday, Oct. 19, 2021. At the lab, a team of young scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. “The excitement is around learning how we harness mRNA technology to develop a COVID-19 vaccine,” Fenner said. ​(AP Photo/Jerome Delay) (I’d cut the last sentence) © Provided by Associated Press Caryn Fenner, Afrigen Biologics and Vaccines technical director, is reflected in a mirror inside a research lab in Cape Town, South Africa, Tuesday, Oct. 19, 2021. At the lab, a team of young scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. “The excitement is around learning how we harness mRNA technology to develop a COVID-19 vaccine,” Fenner said. ​(AP Photo/Jerome Delay) (I’d cut the last sentence)

The U.N.-backed effort to even out global vaccine distribution, known as COVAX, has failed to alleviate dire shortages in poor countries. Donated doses are coming in at a fraction of what is needed to fill the gap. Meanwhile, pressure for drug companies to share, including Biden administration demands on Moderna, has led nowhere.

BioNTech to work with Senegal, Rwanda to make mRNA vaccines

  BioNTech to work with Senegal, Rwanda to make mRNA vaccines DAKAR, Senegal (AP) — Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa. BioNTech, which developed the Pfizer-BioNTech COVID-19 vaccine, said Tuesday that construction will start in mid-2022. It is working with the Institut Pasteur in Dakar, Senegal’s capital, and the Rwandan government, a statement said. “State-of-the-artBioNTech, which developed the Pfizer-BioNTech COVID-19 vaccine, said Tuesday that construction will start in mid-2022. It is working with the Institut Pasteur in Dakar, Senegal’s capital, and the Rwandan government, a statement said.

Second, these vaccines , Pfizer in particular, are the cornerstone of the US-led global vaccination effort that has now pledged 1 billion doses to poor countries. To be perfectly clear, I am not advocating against taking mRNA vaccines . These vaccines are shown to be highly effective against transmission, hospitalization and death, so of course you should take them. Any potential risks are far outweighed by potential complications from actually catching Covid-19, especially as more virulent variants, like the Delta or Gamma variants, become predominant in many parts of the world.

Emile Hendricks, a biotechnologist at Afrigen Biologics and Vaccines in Cape Town, South Africa, poses for a portrait Tuesday, Oct. 19, 2021. He is part of a team of young scientists that is preparing to reverse engineer Moderna's coronavirus vaccine.  “We are doing this for Africa at this moment, and that drives us,” Hendricks said. ​(AP Photo/Jerome Delay) © Provided by Associated Press Emile Hendricks, a biotechnologist at Afrigen Biologics and Vaccines in Cape Town, South Africa, poses for a portrait Tuesday, Oct. 19, 2021. He is part of a team of young scientists that is preparing to reverse engineer Moderna's coronavirus vaccine. “We are doing this for Africa at this moment, and that drives us,” Hendricks said. ​(AP Photo/Jerome Delay)

Until now, WHO has never directly taken part in replicating a novel vaccine for current global use over the objections of the original developers. The Cape Town hub is intended to expand access to the novel messenger RNA technology that Moderna, as well as Pfizer and German partner BioNTech, used in their vaccines.

“This is the first time we’re doing it to this level, because of the urgency and also because of the novelty of this technology,” said Martin Friede, a WHO vaccine research coordinator who is helping direct the hub.

Dr. Tom Frieden, the former head of the U.S. Centers for Disease Control and Prevention, has described the world as “being held hostage” by Moderna and Pfizer, whose vaccines are considered the most effective against COVID-19. The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines.

Vikings' Kirk Cousins, Nate Stanley expected to return Thursday from COVID-19 list

  Vikings' Kirk Cousins, Nate Stanley expected to return Thursday from COVID-19 list Kirk Cousins and backup Nate Stanley are expected to return to practice Thursday. Both were deemed high-risk close contacts when Kellen Mond tested positive for the coronavirus. Minnesota coach Mike Zimmer would not say when Mond, who must miss at least 10 days per the league's protocols, may be back at practice. Vikings cornerback and eight-time Pro Bowler Patrick Peterson has campaigned for more of his teammates to get their COVID-19 vaccine shots amid reports that only 64.5% of Minnesota players are fully vaccinated.

Arguing that American taxpayers largely funded Moderna's vaccine development, the Biden administration has insisted the company must expand production to help supply developing nations. The global shortfall through 2022 is estimated at 500 million and 4 billion doses, depending on how many other vaccines come on the market.

“The United States government has played a very substantial role in making Moderna the company it is,” said David Kessler, the head of Operation Warp Speed, the U.S. program to accelerate COVID-19 vaccine development.

Kessler would not say how far the administration would go in pressing the company. “They understand what we expect to happen,” he said.

Moderna has pledged to build a vaccine factory in Africa at some point in the future. But after pleading with drugmakers to share their recipes, raw materials and technological know-how, some poorer countries are done waiting.

Frances Lees, an engineer for Afrigen Biologics and Vaccines, poses for a photo in Cape Town, South Africa on Tuesday, Oct. 19, 2021. A team of Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. The scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in both vaccine sales and manufacturing. (AP Photo/Jerome Delay) © Provided by Associated Press Frances Lees, an engineer for Afrigen Biologics and Vaccines, poses for a photo in Cape Town, South Africa on Tuesday, Oct. 19, 2021. A team of Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. The scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in both vaccine sales and manufacturing. (AP Photo/Jerome Delay)

Afrigen Managing Director Petro Terblanche said the Cape Town company is aiming to have a version of the Moderna vaccine ready for testing in people within a year and scaled up for commercial production not long after.

FDA panel recommends Pfizer vaccine for kids 5-11; maker of COVAXIN looks to start US trials of vaccine: COVID-19 updates

  FDA panel recommends Pfizer vaccine for kids 5-11; maker of COVAXIN looks to start US trials of vaccine: COVID-19 updates Children are one step closer to being able to receive a COVID-19 vaccine. Ocugen plans to begin US trials of COVAXIN in US. Latest updates.The resounding support is a major step forward for making school-age children eligible for inoculation — likely by next week — but there are still three crucial hurdles to clear: The FDA will have to sign off, an independent CDC advisory panel will review the data, and then the CDC director would have to give her clearance.

Donald Mjonono, an engineer at Afrigen Biologics and Vaccines ​in Cape Town, South Africa, poses for a photograph Tuesday, Oct. 19, 2021. In a pair of warehouses converted into labs, a team of Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. The scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in vaccine sales and manufacturing. ​(AP Photo/Jerome Delay) © Provided by Associated Press Donald Mjonono, an engineer at Afrigen Biologics and Vaccines ​in Cape Town, South Africa, poses for a photograph Tuesday, Oct. 19, 2021. In a pair of warehouses converted into labs, a team of Afrigen scientists is assembling the equipment needed to reverse engineer Moderna's coronavirus vaccine. The scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in vaccine sales and manufacturing. ​(AP Photo/Jerome Delay)

“We have a lot of competition coming from Big Pharma. They don’t want to see us succeed," Terblanche said. "They are already starting to say that we don’t have the capability to do this. We are going to show them.”

If the team in South Africa succeeds in making a version of Moderna’s vaccine, the information will be publicly released for use by others, Terblanche said. Such sharing is closer to an approach U.S. President Joe Biden championed in the spring and the pharmaceutical industry strongly opposes.

Scientists conduct research at an Afrigen Biologics and Vaccines lab in Cape Town, South Africa, Tuesday Oct. 19, 2021. In a pair of warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world's poor. (AP Photo/Jerome Delay) © Provided by Associated Press Scientists conduct research at an Afrigen Biologics and Vaccines lab in Cape Town, South Africa, Tuesday Oct. 19, 2021. In a pair of warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world's poor. (AP Photo/Jerome Delay)

Commercial production is the point at which intellectual property could become an issue. Moderna has said it would not pursue legal action against a company for infringing on its vaccine rights, but neither has it offered to help companies that have volunteered to make its mRNA shot.

South Africa's power cuts a key issue in local elections

  South Africa's power cuts a key issue in local elections JOHANNESBURG (AP) — As South Africa heads into crucial local elections Monday, the country has been hit by a series of crippling power blackouts that many critics say highlight poor governance. With South African residents and businesses struggling to cope with cuts in electricity for up to six hours a day, the government’s failure to provide a stable power supply is a burning election issue. The country’s state-owned power utility Eskom, which provides about 90% of South Africa’s electricity, has for years been marred by allegations of mismanagement and corruption.

Chairman Noubar Afeyan said Moderna determined it would be better to expand production itself than to share technology and plans to deliver billions of additional doses next year.

“Within the next six to nine months, the most reliable way to make high-quality vaccines and in an efficient way is going to be if we make them,” Afeyan said.

Zoltan Kis, an expert in messenger RNA vaccines at Britain’s University of Sheffield, said reproducing Moderna’s vaccine is “doable” but the task would be far easier if the company shared its expertise. Kis estimated the process involves fewer than a dozen major steps. But certain procedures are tricky, such as sealing the fragile messenger RNA in lipid nanoparticles, he said.

Equipment waiting to be assembled and calibrated sits at an Afrigen Biologics and Vaccines lab facility in Cape Town, South Africa, Tuesday, Oct. 19, 2021. In a pair of warehouses converted into airlocked sterile rooms, Afrigen scientists are assembling and calibrating the equipment needed to reverse engineer Moderna’s coronavirus vaccine. ​(AP Photo/Jerome Delay) © Provided by Associated Press Equipment waiting to be assembled and calibrated sits at an Afrigen Biologics and Vaccines lab facility in Cape Town, South Africa, Tuesday, Oct. 19, 2021. In a pair of warehouses converted into airlocked sterile rooms, Afrigen scientists are assembling and calibrating the equipment needed to reverse engineer Moderna’s coronavirus vaccine. ​(AP Photo/Jerome Delay)

“It’s like a very complicated cooking recipe,” he said. “Having the recipe would be very, very helpful, and it would also help if someone could show you how to do it.”

A U.N.-backed public health organization still hopes to persuade Moderna that its approach to providing vaccines for poorer countries misses the mark. Formed in 2010, the Medicines Patent Pool initially focused on convincing pharmaceutical companies to share patents for AIDS drugs.

“It’s not about outsiders helping Africa,” Executive Director Charles Gore said of the South Africa vaccine hub. “Africa wants to be empowered, and that’s what this is about.”

It will eventually fall to Gore to try to resolve the intellectual property question. Work to recreate Moderna's COVID-19 vaccine is protected as research, so a potential dispute would surround steps to sell a replicated version commercially, he said.

“It’s about persuading Moderna to work with us rather than using other methods,” Gore said.

He said the Medicines Patent Pool repeatedly tried but failed to convince Pfizer and BioNTech - the first companies out with an effective vaccine - to even discuss sharing their formulas.

Rep. Raja Krishnamoorthi, who is among the members of Congress backing a bill that calls on the United States to invest more in making and distributing COVID-19 vaccines in low-and middle-income countries, said reverse engineering isn’t going to happen fast enough to keep the virus from mutating and spreading further.

“We need to show some hustle. We have to show a sense of urgency, and I’m not seeing that urgency,” he said. “Either we end this pandemic or we muddle our way through.”

Campaigners argue the meager amount of vaccines available to poorer countries through donations, COVAX and purchases suggests the Western-dominated pharmaceutical industry is broken.

“The enemy to these corporations is losing their potential profit down the line,” Joia Mukherjee, chief medical officer of the global health nonprofit Partners in Health, said. “The enemy isn’t the virus, the enemy isn’t suffering.”

Back in Cape Town, the promise of using mRNA technology against other diseases motivates the young scientists.

“The excitement is around learning how we harness mRNA technology to develop a COVID-19 vaccine,” Caryn Fenner, Afrigen's technical director, said. But more important, Fenner said, “is not only using the mRNA platform for COVID, but for beyond COVID.”

___

Cheng reported from London; Hinnant reported from Paris.

Adar Poonawalla: He vaccinates half the world's babies. Ending the pandemic proved much harder .
As Covid-19 wreaked havoc around the world last year, the 39-year-old son of an Indian billionaire was laying the groundwork for a plan he hoped would eventually end the pandemic. © Dhiraj Singh/Bloomberg/Getty Images Adar Poonawalla, CEO of Serum Institute of India, chose to commit to making a vaccine while it was still in clinical trials. Adar Poonawalla — the CEO of Serum Institute of India (SII), the world's largest vaccine maker — pumped hundreds of millions of dollars into his Indian manufacturing facility and committed to make millions of doses of a then-unproven coronavirus vaccine.

See also